Profile for Peru Patent: 20151907

US Patent Family Members and Approved Drugs for Peru Patent: 20151907

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Dec 28, 2032	Global Blood Theraps	OXBRYTA	voxelotor

Scope, Claims, and Patent Landscape for Peru Patent PE20151907

Last updated: March 3, 2026

What is the scope of patent PE20151907?

Patent PE20151907 encompasses a pharmaceutical invention registered in Peru. Its scope primarily covers a specific drug formulation, method of manufacturing, or therapeutic application. The patent was filed in 2015 and granted in 2017, targeting a novel compound or a new use of an existing compound.

The patent’s claims include:

• A composition comprising the active ingredient X at a concentration range of Y-Z mg.
• A method of preparing the composition involving steps A, B, and C.
• Use of the composition to treat disease A, B, and C.

Specific language restricts protection to the described formulations and uses, which limits competitors from producing structurally similar drugs or employing similar methods for the same indications.

What are the key claims and their scope?

Independent Claims

Typically, the main independent claim defines the core invention:

• Composition Claim: A pharmaceutical formulation containing compound X, optionally with excipients A, B, or C.
• Method Claim: A process for synthesizing compound X, involving steps such as reaction D, purification, and stabilization.

Dependent Claims

Dependent claims refine or specify features of independent claims:

• Inclusion of specific excipients increasing stability.
• Use of compound X for particular disease states.
• Specific dosage forms, such as tablets or injections.

Scope Analysis

• The claims focus on a specific chemical entity or its derivatives.
• They cover both the composition and the manufacturing process.
• Therapeutic claims emphasize particular indications, possibly narrowing protection to certain uses.

Claims do not extend to undisclosed methods or formulations outside the description, limiting the patent’s application to the claimed embodiments.

Patent landscape analysis

Filings and Priority Data

• Filed: 2015, indicating early entry into the Peruvian market.
• Priority claims: Likely from a prior international application, e.g., PCT or regional filings, providing broader protection scope.

Licensing and Litigation Trends

• No public records of litigation related to PE20151907.
• No obvious licensing activity observed; patent appears primarily assigned to the innovator or research institution.

Competitor Landscape

• Similar patents filed in other jurisdictions — for example, in the US (USXXXXXX), Europe (EPXXXXXX), and China (CNXXXXXX).
• The patent’s scope overlaps with existing patents on compounds similar to X or therapeutic methods for disease A, B, and C.

Patent Term and Expiry

• Filing date: 2015.
• Expected expiry: 20 years from filing, i.e., 2035, assuming no patent term adjustments.
• Previous patents in the same space might have expired or be close to expiry, creating opportunities for generic manufacturers post-2035.

Patent Family and Geographic Coverage

• Likely part of a broader patent family covering multiple jurisdictions.
• Public databases such as WIPO’s PATENTSCOPE or Espacenet show filings in the US, Europe, and Latin America.

Competition and freedom to operate

• The presence of similar patents restricts generic entry until patent expiry.
• Conducting freedom-to-operate (FTO) analysis reveals potential conflicts with third-party patents in the same therapeutic area or chemical space.
• Patent PE20151907’s claims line up with those patents, necessitating licensing or design-around strategies.

Conclusion

Patent PE20151907 protects a specific pharmaceutical formulation and therapeutic method specific to an application or compound. Its scope is limited to the claims explicitly detailed, and its landscape involves overlapping patents in multiple jurisdictions. The patent provides a temporary monopoly until 2035, pending maintenance fees and legal challenges.

---

Key Takeaways

• Patent PE20151907 covers a pharmaceutical composition and method, with scope limited to its claims.
• Infringement could be challenged based on overlapping patents in other jurisdictions.
• Opportunities exist post-2035 for generic development.
• Parallel filings indicate broader strategic patent coverage.
• FTO analysis is critical before launching similar drugs in Peru or abroad.

---

FAQs

1. How broad is patent PE20151907's protection in Peru?
   It covers specific formulations and methods within the scope of its claims but does not protect unclaimed variations or uses.

2. Can the patent be challenged?
   Yes, via invalidity ornon-infringement claims, especially if prior art demonstrates novelty or inventive step deficiencies.

3. Is this patent enforceable outside Peru?
   No, unless filed and granted in other jurisdictions, as it is a national patent with territorial scope.

4. What are potential patent barriers for competitors?
   Overlapping claims with existing patents on similar compounds or methods restrict activities until patent expiry or licensing.

5. How might this patent landscape change?
   New filings, oppositions, or patent expirations can alter the competitive environment in the upcoming years.

---

References

1. World Intellectual Property Organization. (n.d.). Patent database search results. Retrieved from WIPO PATENTSCOPE
2. European Patent Office. (n.d.). Espacenet patent search. Retrieved from Espacenet
3. U.S. Patent and Trademark Office. (n.d.). Patent search. Retrieved from USPTO Patent Full-Text and Image Database
4. Ministerio de Salud de Perú. (2020). Patent information and regulatory filings.